argenx SE (ARGX) stock
ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 19, 2026Score 5/30
$941.25−6.27 (-0.66%)
Close on Nov 18, 2026Market cap –P/E 48.1Yield –
argenx revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2023 it was $35.53M, up 254.4% from the year before. The highest annual figure on record is $497.28M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $35.53M | +254.4% |
| FY2022 | Dec 31, 2022 | $10.03M | -98.0% |
| FY2021 | Dec 31, 2021 | $497.28M | +1105.7% |
| FY2020 | Dec 31, 2020 | $41.24M | -47.4% |
| FY2019 | Dec 31, 2019 | $78.46M | +265.2% |
| FY2018 | Dec 31, 2018 | $21.48M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | $96.00M | – |
See a number that looks wrong?